What Boston Scientific's latest 10-Q says: 10 signals
Boston Scientific filed its latest 10-Q with the SEC on Aug 3, 2026. It discusses acquisition announced, acquisition completed and bookings decline.
Public (BSX)Medical Equipment Manufacturing10,000+ employeesbostonscientific.comLinkedIn
- Filed
- Aug 3, 2026
- Filings
- 2
- Signals
- 22
10-Q · latest 10
What Boston Scientific's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 10 signals
BSX secures $8B in credit facilities for pending acquisition of Penumbra, Inc.
Boston Scientific has arranged a $2 billion revolving credit agreement and a $6 billion term loan to fund the pending acquisition of Penumbra, Inc.
$8B
Total credit facilities (revolving credit and term loan) arranged to fund the pending acquisition of Penumbra, Inc.
Penumbra, Inc.
BSX spent $718M on acquisitions in H1 2026, primarily for Nalu Medical, Inc.
The company invested $718 million in cash for acquisitions in the first half of 2026, with Nalu Medical, Inc.
$718M
Net cash payments for acquisitions of multiple businesses during the first six months of 2026.
Nalu Medical, Inc.MiRus LLCBolt Medical, Inc.SoniVie Ltd.
BSX faces increased competition and slowing growth for its WATCHMAN™ device.
The company is experiencing a slowdown in its key WATCHMAN™ procedures and increased competition in its Electrophysiology unit.
Urology business underperforms due to China VBP and 'commercial disruption'.
The Urology business is facing flat growth due to underperformance in its stone franchise from China's volume-based procurement policies and 'commercial disruption' in its sacral neuromodulation franchise.
1.1%
Urology reported net sales growth for Q2 2026.
New products AGENT™ and Farapulse™ drive strong growth in Cardiovascular unit.
The Cardiovascular business, a key segment, is experiencing significant growth driven by the successful commercialization of its AGENT™ Drug-Coated Balloon and Farapulse™ Pulsed Field Ablation (PFA) System.
Drug-Coated BalloonPulsed Field Ablation (PFA)
Spent $372M on property, equipment, and internal use software in H1 2026
The company invested $372 million in capital expenditures, which includes internal use software, during the first six months of the year.
$372M
Purchases of property, plant and equipment and internal use software in the first six months of 2026.
internal use software
BSX increases R&D spending by $100M (10%) to build future product pipeline.
The company increased R&D expenses by $100 million in the first half of 2026, a 10% year-over-year rise, to maintain a robust pipeline of new products.
$100M
Increase in R&D expenses in H1 2026 vs H1 2025.
10%
Increase in R&D expenses in H1 2026 vs H1 2025.
- SEC EDGAR
10-Q
Filed · 12 signals
Planning $14.5B acquisition of Penumbra, Inc., to close in H2 2026, funded by $11B in new debt.
This massive acquisition will create significant post-merger integration challenges, requiring consolidation of ERP, CRM, HRIS, and supply chain systems.
$14.5B
Purchase price for the acquisition of Penumbra, Inc.
Penumbra, Inc.
BSX to acquire Penumbra for ~$14.5B, deal faces FTC review.
BSX announced a definitive agreement to acquire Penumbra for ~$14.5B, to be funded with ~$11B in new debt.
$14.5B
Announced purchase price for Penumbra, Inc.
Acquired Nalu Medical, Inc. for $523M in Q1 2026, triggering immediate integration activities.
The recent acquisition of Nalu Medical necessitates the integration of its people, processes, and technology into Boston Scientific's ecosystem.
$523M
Net cash payments for the acquisition of Nalu Medical, Inc.
Nalu Medical, Inc.
Showing 10 of 22 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Boston Scientific earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Failed ERP upgrade causes $30M backorder in EuropeA recent ERP system implementation at a key European distribution center failed, resulting in a significant $30 million backorder. This major operational disruption creates an urgent need for system integration, supply chain optimization, and IT consulting services to resolve the issue and prevent future failures. | |
| Aggressively investing to become the #1 market share leader in EP.With its EP business growing 63%, the company explicitly stated its aim to become the overall EP market share leader. This aggressive goal to dethrone incumbents implies heavy investment in commercial resources, R&D, and marketing to sustain momentum and win. | |
| Acknowledges product 'gap' in CRM business, plans major tech refreshLeadership acknowledged a product 'gap' in the leadless pacemaker market is causing the Core CRM business to grow below market. They are investing in a complete platform refresh ('Denali') and a new leadless product ('EMPOWER') to regain competitiveness, signaling budget for R&D, product development, and go-to-market support. | |
| Targeting 50 bps of annual operating margin expansionThe company has a multi-year goal to expand adjusted operating margins by approximately 50 basis points annually. This creates a strong incentive to evaluate any technology or service that can drive operational efficiency, automate processes, or reduce operating expenses. | |
| Reports $181M in Q3 net capital expenditures to fund growth.The company spent $181 million on net capital expenditures in the quarter, part of a plan to generate $3.5 billion in free cash flow for the year. This level of CapEx supports infrastructure, facilities, and equipment needed for its rapid growth and product launches. | |
| Investing in AI software to solve unmet clinical needsBoston Scientific is actively integrating AI into its product ecosystem, such as the 'Cortex AI algorithm,' to create differentiated value and address complex medical challenges. This focus on software and AI signals an appetite for advanced analytics, machine learning platforms, and specialized software development partnerships. |
Signal API · MCP
Track Boston Scientific with the Signal API
One POST /v1/companies/enrich call with bostonscientific.com returns Boston Scientific 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Boston Scientific 10-Q
When did Boston Scientific file its latest 10-Q?
What did Boston Scientific disclose in its latest 10-Q?
What did Boston Scientific say on its recent earnings calls?
Where can I read Boston Scientific's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .